FDA to Consider Patient Perspective in Drug Development
The FDA is launching a new program in which they will consider and incorporate the patient perspective into drug development. They will choose 20 diseases for the program and the MRF is lobbying to have melanoma be one of them. As we all know, the patient perspective is important in any disease, but it is especially true with melanoma.
Here is my letter to the FDA expressing this great need in the field of melanoma.